Navigation Links
Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies


The Epstein Barr virus (EBV), which causes infectious mononucleosis (IM), is one of the most common human viruses. EBV occurs worldwide, and most people become infected with EBV sometime during their lives. In the United States, as many as 95 percent of adults between 35 and 40 years of age have been infected. In most developed countries, including the U.S., infection with EBV most often occurs during adolescence or young adulthood, causing infectious mononucleosis in 35 percent to 50 percent of infected individuals.

While treatment of IM normally entails mere bed rest and adequate intake of fluids and the disease is typically self-limiting, it can be devastating in immunocompromised patients and occasionally precipitates serious complications that can include: coronary and neurologic infections, compromised respiration secondary to acute lymphadenopathy, anemia and ruptured spleen. Therefore, accurate diagnosis and prompt treatment of complications is important. Differential diagnosis of IM is also useful in ruling out other mononucleosis-like illnesses induced by cytomegalovirus, adenovirus, or Toxoplasma gondii.

The characteristic triad of fever, pharyngitis, and lymphadenopathy lasting for one to four weeks, together with the age of the patient (most typically adolescent) suggest the clinical diagnosis of (IM). Laboratory tests are usually advisable for confirmation. Serologic findings include a normal to moderately elevated white blood cell count, an increased total number of lymphocytes and greater than 10 percent atypical lymphocytes. In keeping with the rapid proliferation of point-of-care diagnostic kits and devices, several products have now been CLIA-waived by the Centers for Disease Control and Prevention (CDC).

At present, 13 biomedical manufacturers produce 17 distinct test kit products that have gained CLIA waivers.

Thermo Electron Corporation, Waltham, Mass., manufactures the BioStar Acceava Mono Test for both C
'"/>




Page: 1 2 3

Related medicine technology :

1. Rapid Flu Tests May Prove Especially Helpful This Season
2. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
3. Avian (Bird) Flu: Is There a Role for Rapid Tests?
4. Rapid HIV Testing Increases Possibility of Treatment
5. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
6. PSA TestingHow Much is Too Much?
7. Hemoglobin Testing at the Point of Care
8. Testing for Human Papillomavirus
9. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
Post Your Comments:
(Date:7/29/2014)... 29, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... second quarter 2014 financial results on Tuesday, August 5, ... Company,s management will hold a conference call at 8:00 ... 8:00 p.m., Beijing Time on August 6, 2014, to ...
(Date:7/29/2014)... , July 29, 2014 , ... /Oxymorphone clinical development program has commenced , ... Australia during Q4 2014 , ... States in 1H 2015 Australian drug ... on its opioid transdermal patch programs after its recent announcement of ...
(Date:7/29/2014)... ROCKLAND, Massachusetts , July 29, 2014 ... an international Phase II study investigating the efficacy and safety ... mMCC is a rare and aggressive skin cancer ... explored in a seven cohort Phase I clinical trial for ... patients  , EMD Serono, Inc., a subsidiary of ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... First Extensive Report of Bile Acid Aberration in Type 2 Diabetes ... ... N.J., June 9 /PRNewswire-FirstCall/,-- KineMed, Inc., and Daiichi Sankyo, Inc., announced ... people with type 2,diabetes which may suggest a newly identified underlying ...
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
Cached Medicine Technology:New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 2New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 3New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 4New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 5New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 6New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 7Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
(Date:7/29/2014)... TN (PRWEB) July 29, 2014 The ... the reimbursement model of all hospitals. Studies show that ... One simple, easy, low cost tool that great ... performance by 20 to 25%. , Their secret? Debriefing ... one anther at the end of an operational event. ...
(Date:7/29/2014)... to a more streamlined process for obtaining stem cells, which ... tissue for failing body parts, according to UC San Francisco ... Cell . , The work builds on a strategy ... in which they again have the potential to become any ... may soon increase thanks to the scientists, identification of biochemical ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... July 29, 2014 The Eleventh Annual ... Summit concluded with the $10,000 prize being presented to ... http://www.bikanta.com ) , The 11th Annual Summit was held ... entrepreneurs who can bring innovative products and services for ... pleased to have had such excellent array of young ...
(Date:7/29/2014)... Lean and Lovely, an affordable and short program, claims ... wear a bikini in the near future. This has caught ... , “Our Lean and Lovely review shows that ... levels. Neither your age nor your body shape matters, which ... the beginning, you will achieve the results that you have ...
Breaking Medicine News(10 mins):Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Stem cell advance may increase efficiency of tissue regeneration 2Health News:Stem cell advance may increase efficiency of tissue regeneration 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:Lean and Lovely: Review Examining Neghar Fonooni’s Program Released 2
... WASHINGTON, July 9 The Pharmaceutical Care,Management Association ... the Medicare bill, which includes a provision that ... "The inclusion of an e-prescribing requirement in ... a patient,s perspective, e-prescribing,is the most important issue ...
... Protect Patient Access To Community,Pharmacies, ALEXANDRIA, ... voted by unanimous consent in favor of ... Providers Act of 2008 contains three critical,provisions ... D claims, delayed cuts to Medicaid generic ...
... patients with the blood cancer , , WEDNESDAY, July 9 ... once-banned drug thalidomide for patients with myeloma have learned ... is to science: Don,t judge results too early. , ... increased the odds of a complete remission, but not ...
... Counseling for All Combat Veterans, WASHINGTON, July 9 ... in 39 additional,communities across the country where the Department ... 2009., "Community-based Vet Centers -- already in all ... health program," said Dr. James B. Peake,Secretary of Veterans ...
... body,s ability to repair sperm DNA, studies find , , ... over- or underweight can have a negative effect on ... to be presented July 9 at the annual conference ... in Barcelona, Spain. , While semen samples from diabetics ...
... Ind., July 9 Zimmer Holdings, Inc.,(NYSE and SWX: ... conference call will be broadcast live over the Internet ... A news release,detailing the quarterly results will be made ... The live audio webcast can be accessed via ...
Cached Medicine News:Health News:Thalidomide Continues to Show Benefits Against Myeloma 2Health News:Thalidomide Continues to Show Benefits Against Myeloma 3Health News:VA Vet Centers Coming to 39 Communities 2Health News:Diabetes, Weight Tied to Male Infertility 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: